Functional Proteomic Profiling of Triple-Negative Breast Cancer.
breast cancer
proteomics
reverse phase protein array
signaling pathway profiling
triple negative breast cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
18
08
2021
revised:
08
09
2021
accepted:
26
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that comprises various disease entities, all of which share a set of common features: a lack of expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, respectively. Because of their receptor status, conventional chemotherapy remains the main therapeutic option for TNBC patients. We employed a reverse phase protein array approach (RPPA), complemented by immunohistochemistry, to quantitatively profile the activation state of 84 actionable key signaling intermediates and phosphoproteins in a set of 44 TNBC samples. We performed supervised and unsupervised approaches to proteomic data analysis to identify groups of samples sharing common characteristics that could be amenable to existing therapies. We found the heterogenous activation of multiple pathways, with PI3 K/AKT/mTOR signaling being the most common event. Some specific individualized therapeutic possibilities include the expression of oncogenic
Identifiants
pubmed: 34685748
pii: cells10102768
doi: 10.3390/cells10102768
pmc: PMC8535076
pii:
doi:
Substances chimiques
Neoplasm Proteins
0
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : A Race against Breast Cancer foundation
ID : n/a
Références
Mol Oncol. 2010 Dec;4(6):539-61
pubmed: 21036680
Mol Oncol. 2015 Oct;9(8):1636-54
pubmed: 26026368
BMJ. 2010 Aug 11;341:c3620
pubmed: 20702548
Nat Rev Clin Oncol. 2016 May;13(5):305-18
pubmed: 26620272
Sci Rep. 2019 Feb 7;9(1):1538
pubmed: 30733547
Cell Rep. 2015 Apr 7;11(1):111-24
pubmed: 25818297
Oncologist. 2007 Jan;12(1):20-37
pubmed: 17227898
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
Cell Biosci. 2014 Oct 01;4(1):59
pubmed: 25309720
Oncotarget. 2015 Sep 29;6(29):26560-74
pubmed: 26387133
Mol Oncol. 2010 Jun;4(3):209-29
pubmed: 20537966
PLoS One. 2015 Nov 05;10(11):e0141763
pubmed: 26540293
Cancer Cell. 2011 Jan 18;19(1):86-100
pubmed: 21215703
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4280-5
pubmed: 25120810
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Br J Surg. 2013 Mar;100(4):490-6
pubmed: 23319435
Mol Cell Proteomics. 2013 Feb;12(2):381-94
pubmed: 23172894
J Cell Biol. 2007 Apr 9;177(1):87-101
pubmed: 17420292
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
Stem Cells. 2005;23(1):16-43
pubmed: 15625120
Breast Care (Basel). 2015 Jul;10(3):159-66
pubmed: 26557820
Ann Oncol. 2014 Oct;25(10):1973-1979
pubmed: 25009009
Proteomics Clin Appl. 2009 Apr;3(4):412-22
pubmed: 21136968
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
FEBS J. 2009 Dec;276(23):6871-9
pubmed: 19860827
J Natl Cancer Inst. 2006 Jul 19;98(14):1011-4
pubmed: 16849684
Mol Oncol. 2008 Dec;2(4):368-79
pubmed: 19383358
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Oncotarget. 2017 Jul 31;8(41):70481-70495
pubmed: 29050296
Mol Oncol. 2007 Dec;1(3):321-49
pubmed: 19383306
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Biochim Biophys Acta. 2014 May;1844(5):950-9
pubmed: 24361481
Clin Cancer Res. 2008 Dec 15;14(24):8010-8
pubmed: 19088017
Clin Breast Cancer. 2015 Dec;15(6):473-481.e3
pubmed: 26051240
Breast Cancer Res. 2015 Mar 20;17:43
pubmed: 25887482
Methods Enzymol. 2006;411:134-93
pubmed: 16939790
Breast Cancer Res. 2015 Mar 04;17:31
pubmed: 25849541
Oncogene. 2004 Jun 10;23(27):4745-53
pubmed: 15122336
Nat Methods. 2013 Nov;10(11):1046-7
pubmed: 24037243
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proteomics. 2007 Nov;7(22):4066-8
pubmed: 17952872
Br J Cancer. 2009 May 19;100(10):1517-22
pubmed: 19367275
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Oncologist. 2013;18(2):123-33
pubmed: 23404817
Breast Cancer Res Treat. 2014 Jun;145(2):339-48
pubmed: 24771047